Protagonist Therapeutics (NASDAQ:PTGX) Given New $125.00 Price Target at Citigroup

Protagonist Therapeutics (NASDAQ:PTGX) had its price objective increased by Citigroup from $115.00 to $125.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, February 17th. The Goldman Sachs Group upped their price objective on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the company a “neutral” rating in a research note on Tuesday, March 3rd. Jefferies Financial Group reiterated a “buy” rating and set a $121.00 target price on shares of Protagonist Therapeutics in a report on Wednesday. Truist Financial boosted their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Barclays upped their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $107.31.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $101.68 on Thursday. The firm has a market cap of $6.49 billion, a PE ratio of -49.60 and a beta of 2.23. Protagonist Therapeutics has a fifty-two week low of $39.60 and a fifty-two week high of $105.69. The business has a 50 day moving average price of $86.80 and a 200-day moving average price of $80.59.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The firm had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. Research analysts predict that Protagonist Therapeutics will post 2.43 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Dinesh V. Ph D. Patel sold 34,438 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $82.48, for a total value of $2,840,446.24. Following the completion of the sale, the chief executive officer directly owned 580,505 shares of the company’s stock, valued at approximately $47,880,052.40. This trade represents a 5.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Asif Ali sold 46,203 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the sale, the chief financial officer directly owned 60,320 shares in the company, valued at $5,014,401.60. The trade was a 43.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 203,167 shares of company stock worth $16,889,199. Company insiders own 4.90% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

Several large investors have recently bought and sold shares of the company. Rockefeller Capital Management L.P. grew its holdings in shares of Protagonist Therapeutics by 10.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 3,292 shares of the company’s stock worth $288,000 after acquiring an additional 312 shares during the period. Seven Fleet Capital Management LP purchased a new position in shares of Protagonist Therapeutics in the 4th quarter valued at approximately $699,000. Invesco Ltd. boosted its position in shares of Protagonist Therapeutics by 56.2% during the fourth quarter. Invesco Ltd. now owns 1,567,840 shares of the company’s stock valued at $136,935,000 after purchasing an additional 564,134 shares in the last quarter. KVP Capital Advisors LP bought a new stake in shares of Protagonist Therapeutics during the fourth quarter valued at approximately $4,629,000. Finally, Virtus Investment Advisers LLC grew its stake in Protagonist Therapeutics by 38.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 2,790 shares of the company’s stock worth $244,000 after purchasing an additional 770 shares during the period. 98.63% of the stock is owned by institutional investors.

Key Headlines Impacting Protagonist Therapeutics

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval and commercial terms: Johnson & Johnson’s U.S. FDA approval of ICOTYDE—an oral IL‑23R targeted peptide developed with Protagonist—triggered a $50 million milestone payment to Protagonist and makes the company eligible for 6–10% royalties plus up to $580 million in future milestones, creating a clear near‑ and long‑term revenue path tied to J&J’s commercialization. AccessWire: FDA approval and deal terms
• Positive Sentiment: Major analyst upgrades/price‑target lifts: Several firms raised targets and reiterated positive ratings today—Citigroup to $125 (Buy), Barclays to $119 (Overweight), Leerink to $110 (Outperform), and JPMorgan to $106 (Overweight)—signaling broad Wall Street support and further buying interest. (See links for coverage.) Benzinga: analyst coverage TickerReport: JPMorgan note
• Positive Sentiment: Wall Street commentary: Coverage highlights that J&J’s approval should create “significant value” for Protagonist via milestones and royalties, reinforcing the market narrative that the approval is transformational for PTGX. MSN: Wall Street reaction
• Positive Sentiment: Industry impact commentary: Media coverage frames Protagonist’s first approval as disruptive to larger immunology incumbents, supporting investor expectations of meaningful market share and pricing power if J&J’s launch gains traction. BioSpace: market impact
• Neutral Sentiment: Conference call/transcript and investor materials are available: Protagonist and partners provided conference/webcast materials and a transcript discussing the approval and clinical data; useful for investors wanting primary‑source detail on safety, efficacy, and commercial strategy. Seeking Alpha: transcript Seeking Alpha: slideshow
• Negative Sentiment: Commercial and timing risk: while the approval creates revenue pathways, Protagonist’s near‑term cash flow depends on J&J’s successful launch, market uptake timing, and royalty cadence—factors outside Protagonist’s direct control that could delay or limit realized revenue. AccessWire: deal structure & royalties

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.